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Activation of the MAP Kinase Pathway Induces
Apoptosis in the Merkel Cell Carcinoma Cell Line
UISO
Roland Houben1,3, Sonja Ortmann1,3, David Schrama1, Marco J. Herold2, Ingolf Berberich2,
Holger M. Reichardt2 and Juergen C. Becker1
Merkel cell carcinoma (MCC) is a rare but highly aggressive tumor of the skin. Recently, we have shown that
MCC cells in situ are characterized by a complete absence of mitogen-activated protein kinase (MAPK) pathway
signaling, which is preserved in the MCC cell line UISO. Here we present data suggesting that silencing of the
MAPK pathway is essential for the survival of MCC cells. Activation of the MAPK pathway could be achieved by
inducing a regulatable form of the c-Raf-1 kinase domain in UISO cells. Consequently, MAPK signaling led to
morphological changes, loss of actin stress fibers, and induction of apoptosis, which could be prevented by the
MAP kinase kinase-specific inhibitor U0126. Hence, despite the fact that activation of the MAPK pathway
contributes to oncogenesis in many cancers, it seems to be a negative selection factor for MCC cells. Since ERK
phosphorylation was also inducible by the Raf-activating pharmacological agent ZM336372, these results
provide new perspectives for potential therapeutics for this highly aggressive tumor.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare form of skin cancer of
neuroendocrine origin, with an incidence of 0. 23 per
100,000 people in the Caucasian population of the United
States of America (Poulsen, 2004). The tumors are commonly
located in body areas that are chronically exposed to the sun,
and 95% of the patients with MCC are more than 50 years old
(Miller and Rabkin, 1999). Notably, the genetic and
molecular mechanisms involved in the development and
progression of MCC are not well defined.
Recently, we have reported the virtually complete
inactivity of the mitogen-activated protein kinase (MAPK)
pathway in MCC as assessed by immunohistological analysis
of 49 MCC tumors for expression and phosphorylation of ERK
(Houben et al., 2006). This is in striking contrast to the
majority of cancers, but is shared by some other neuroendo-
crine tumors (Kunnimalaiyaan and Chen, 2006a). The MAPK
pathway is a major regulator of cell growth, differentiation,
and survival and is activated in response to a variety of
extracellular stimuli (Naumann et al., 1997). Upon growth
factor stimulation, the small G-protein Ras is activated, which
leads to the consecutive activation of the three kinases Raf,
MEK (MAP kinase kinase), and ERK (p44/p42 MAP kinases).
The importance of the Ras/Raf/MEK/ERK-signaling path-
way for carcinogenesis is reflected by the observations that
Ras genes (K-ras, H-ras, and N-ras) are the most frequently
mutated oncogenes detected in human cancer (Bos, 1989;
Ellis and Clark, 2000) and that B-Raf is activated in several
malignancies with the highest frequency found in melanoma
(Davies et al., 2002). On the other hand, MAP kinase
pathway activation by itself is not sufficient for malignant
transformation, as high frequencies of activating B-Raf
mutations are also found in benign nevi (Pollock et al.,
2003). Moreover, expression of activated B-Raf or Ras in
primary cells such as melanocytes leads to cell cycle arrest
(Michaloglou et al., 2005). In concordance with the lack of
MAP kinase pathway activation in MCC, we and others did
not detect any B-Raf or Ras mutations in this tumor entity
(Popp et al., 2002; Worda et al., 2005; Houben et al., 2006).
The absence of ERK phosphorylation suggests that MAP
kinase pathway activity might be a negative selection factor
for MCC cells. Using the MCC cell line UISO as a model
system, we demonstrate that activation of the MAP kinase
pathway by means of a hormone regulatable fusion protein,
consisting of the c-Raf-1 kinase domain and a modified
hormone-binding domain of the estrogen receptor (Kerkhoff
et al., 1998), induces apoptosis in these cells.
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RESULTS
Activation of the MAP kinase pathway in MCC cells through a
regulatable form of c-Raf-1 kinase
Fusion of the c-Raf-1 kinase domain (BXB) to a modified
hormone-binding domain of the estrogen receptor results in a
kinase (c-Raf-1-BXB-ERTM, here referred to as Raf-ER) whose
activity is dependent on the presence of 4-hydroxytamoxifen
(OHT), while retaining the same target specificity as Raf
(Kerkhoff and Rapp, 1997). To test whether MAPK signaling is
inducible in MCC cells by Raf kinase activity, we infected
UISO cells with a virus carrying this conditionally active Raf
kinase (UISO-Raf-ER) or the empty EYZ vector (UISO vector).
Neither unstimulated UISO-Raf-ER cells nor OHT-stimulated
UISO-vector cells showed any phosphorylation of ERK
(Figure 1). In contrast, a strong phospho-ERK signal was
detectable in UISO-Raf-ER cells within 1 hour after addition
of OHT, which persisted for 5 days (Figure 1). Notably, the
level of ERK protein was equal in UISO-vector and UISO-Raf-
ER cells and remained unaltered throughout the whole
experiment. It should be further noted that both B-Raf and
MEK were expressed in the UISO cells (Figure 2 and data not
shown); hence, all the core enzymes necessary for classical
MAP kinase pathway signaling were present and functional,
as signal transduction could be induced in UISO cells by
activating Raf-ER. This indicates that silencing of the pathway
in MCC cells actually occurs upstream or at the level of Raf.
Raf activation induces morphological changes and breakdown
of actin stress fibers
In the absence of OHT, UISO-Raf-ER cells like UISO vector
or the parental UISO cells grow as relatively small, flat cells
with rarely appearing extensions of the cell body (Figure 2a).
This appearance, however, rapidly changes after activating
the kinase; 10 hours following OHT stimulation, first cells
start to loose their close attachment to the tissue culture
plates, round up and long cytoplasmic extensions become
prominent. Twenty-four hours after addition of OHT almost
all cells have adopted this phenotype (Figure 2a). The shape
of cells depends on so-called actin stress fibers, which are
major cytoskeletal structures that are linked to the plasma
membrane at focal adhesions (Ridley and Hall, 1992).
Fluorescence staining to visualize intracellular filamentous
actin structures revealed that the actin stress fibers disappear
upon activation of Raf-ER (Figure 2b). Morphology changes
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Figure 1. Induction of ERK phosphorylation by OHT stimulation of
UISO-Raf-ER cells. UISO-Raf-ER cells expressing c-Raf-1-BXB-ERTM and
UISO-vector cells stably transfected with the empty vector were incubated
in the presence of 200 nM OHT for the indicated time. Total cell lysates
were subjected to Western blot analysis and probed with the indicated
antibodies.
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Figure 2. OHT stimulation of UISO-Raf-ER cells induces spindle-shaped morphology and break down of actin stress fibers. (a) Light microscopy
demonstrating morphological changes induced by Raf activation. UISO-Raf-ER or UISO-vector cells were incubated for 24 hours in the presence of 200 nM
OHT or in the presence of the equivalent amount of the solvent EtOH (bar¼ 100mm). (b) Confocal fluorescence microscopy depicting loss of actin stress
fibers upon Raf-ER activation. Forty-eight hours following cultivation of the cells in the presence of OHT or EtOH nuclear staining with DAPI and actin staining
with Phalloidin Alex Fluor 488 was performed (bar¼ 20mm).
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and actin stress fiber breakdown were not observed upon
OHT stimulation of UISO-vector cells (Figure 2a and b).
Raf activation induces apoptosis in UISO MCC cells
Upon prolonged incubation of UISO-Raf-ER cells with OHT,
an increase in completely detached and shrinked cells
became evident, indicating cell death. We therefore analyzed
changes in the viability of the UISO-Raf-ER cells over time
following addition of OHT. We observed an increase in the
percentage of dead cells at 48 hours, reaching a level of 80%
at 120 hours (Figure 3a). In contrast, incubation of UISO-
vector control cells with OHT or UISO-Raf-ER cells with only
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Figure 3. Apoptosis induced by OHT stimulation of UISO-Raf-ER cells. UISO-Raf-ER or UISO-vector control cells were seeded with 2104 cells/well in
96-well plates, followed the next day by addition of either OHT to a final concentration of 200 nM or the solvent ethanol. (a) At the indicated time points
following OHT stimulation, detached and adherent cells were pooled, pelleted, and resuspended in trypan blue solution. The percentage of cells not excluding
trypan blue was plotted against time. (b) OHT was added to UISO Raf-ER cells at varying concentrations. ERK phosphorylation by Western blot analysis
and trypan blue exclusion was measured following 24 and 120 hours, respectively. (c) SKmel28-Raf-ER were incubated either with 200 nM OHT or with the
solvent EtOH and trypan blue exclusion was measured in the course of time. In addition, the level of ERK-phosphorylation following 24 hours in the presence of
OHT is shown. (d) DNA content of UISO-Raf-ER cells was quantitated by propidium iodide staining. Depicted are two examples of flow cytometry histograms
of UISO-Raf-ER cells after 0 or 72 hours of OHT stimulation, respectively. (e) The percentages of apoptotic cells identified by a sub-G1 DNA content are
plotted against time. (f) Proportion of living cells in the different cell cycle phases in the course of time following OHT stimulation. (g) Annexin V staining in the
course of time following OHT stimulation. (h) Trypan blue exclusion assay following 120 hours of incubation of UISO-Raf-ER cells either in the presence of
OHT or the solvent EtOH in combination with the indicted concentration of the caspase inhibitor Z-VAD-FMK.
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the solvent EtOH did not affect their viability. Following
extended incubation of UISO-Raf-ER cells with OHT for 10
days, there were no living cells left (data not shown). Titration
of OHT demonstrated that even weaker Raf activation
associated with only relatively moderate levels of ERK
phosphorylation induced cell death in UISO-Raf-ER cells
(Figure 3b).
To control the specificity of Raf-activation-induced cell
death for UISO cells, we have generated three melanoma cell
lines expressing Raf-ER protein. These cells, which display
ERK phosphorylation already in the absence of OHT, still
showed a strong increase in phospho-ERK upon OHT
stimulation (depicted for SKmel28-Raf-ER cells in Figure
3c). In contrast to UISO-Raf-ER cells, however, for all the
three melanoma cell lines, there were no signs of increased
cell death in OHT-stimulated cells compared with cells
treated with the solvent EtOH (shown for SKmel28-Raf-ER
cells in Figure 3c). Moreover, two further MCC cell lines
MCC13 and MCC26 were transduced with the Raf-ER
construct. For both cell lines, we have shown before that
they display considerable levels of ERK phosphorylation;
therefore, they have not preserved the general in situ MCC
feature of MAPK pathway inactivity (Houben et al., 2006).
Viability of these cells was not affected by MAPK pathway
activation through OHT stimulation (data not shown).
It should be noted that for several non-transformed cell
lines introduction of active Ras or Raf led to cell cycle arrest,
which was at least in some instances mediated by induction
of the tumor suppressor protein p21 (Michaloglou et al.,
2005). Therefore, we performed a cell cycle analysis to
quantitate the distribution of UISO-Raf-ER cells in the
different phases following addition of OHT (Figure 3d).
Measuring the DNA content by flow cytometry revealed that
these slowly cycling UISO-Raf-ER cells contain only a small
proportion of cells in S phase. The relative ratio of living cells
in G1, S and G2/M phases of the cell cycle remained
however relatively constant over a period of 5 days following
Raf-ER activation (Figure 3e).
Using the DNA content analysis, a steady increase in the
percentage of cells with a sub-G1 DNA content became
obvious. This indicates that cell death is accompanied by
DNA degradation, a hallmark of apoptosis (Figure 3f). To
confirm that cell death induced by Raf activation in UISO-
Raf-ER cells indeed occurs through apoptosis, UISO cells
were stained with Annexin V, a well-established apoptosis
marker. Indeed, cells became Annexin V positive in the
course of time following OHT stimulation (Figure 3g). In
addition, we applied the pan-caspase inhibitor Z-VAD-FMK.
In the presence of Z-VAD-FMK, the extent of cell death
induced in UISO-Raf-ER cells by OHT stimulation was
substantially decreased indicating the involvement of cas-
pases in mediating apoptosis (Figure 3h).
The MEK inhibitor U0126 blocks ERK activation, morphological
changes and cell death induced by activation of Raf-ER
The activation of MEK by Raf and the subsequent activation
of ERK by MEK is required to mediate many of the Raf-
induced cellular responses, suggesting that ERK is the
dominant Raf effector protein (Daum et al.,. 1994). However,
accumulating evidence indicates that there are additional Raf
substrates and that subsets of Raf-regulated events are
presumably mediated independently of the MAP kinase
cascade (Pearson et al., 2000; Baumann et al., 2000; O’Neill
et al., 2004; Gotz et al., 2005). Therefore, by use of the MEK
inhibitor U0126, we investigated whether the effects ob-
served in OHT stimulated UISO-Raf-ER cells were indeed
MEK-dependent. U0126 inhibited the OHT-induced phos-
phorylation of ERK, although a relatively high dose of 32 mM
U0126 was necessary to completely block ERK phosphoryla-
tion (Figure 4a). Increasing the concentrations of this MEK
inhibitor, we observed a stepwise-reduced percentage of
OHT-stimulated cells displaying the spindle-shaped mor-
phology (not shown) and at 30mM U0126 no morphological
alterations were evident any longer (Figure 4c). The following
series of experiments addressed whether cell death induced
by activation of Raf-ER was also inhibited by blocking MAP
kinase pathway signaling. In the presence of 5 mM U0126,
which only partially reduced ERK phosphorylation (Figure
4a), a slight delay in the onset of cell death was observed,
whereas in the presence of 30mM U0126, this effect was
much more pronounced (Figure 4b).
MAP kinase pathway activation in UISO cells through a
pharmacogical agent
To further confirm that a functional Raf/MEK/ERK cascade is
present in UISO MCC cells, we took advantage of the low
molecular weight compound ZM336372, which was initially
identified as a c-Raf-1 inhibitor in vitro, but paradoxically
displayed c-Raf-1 activation in cell culture experiments at
higher concentrations (Hall-Jackson et al.,. 1999). Incubation
of UISO cells with ZM336372 at such high concentrations of
100 or 200mM indeed induced phosphorylation of ERK
(Figure 5).
DISCUSSION
Similarly to MCCs in situ ERK phosphorylation is not
detectable in UISO cells (Houben et al., 2006). Here we
demonstrate that MAPK pathway signaling is induced both in
UISO-Raf-ER cells by activating the hormone regulatable Raf
kinase and in UISO cells by the Raf activating agent
ZM336372. Together with the observation that ERK phos-
phorylation in UISO cells cannot be induced by growth factor
stimulation (Houben et al., 2006), these findings suggest that
silencing of the MAPK pathway in MCC cells occurs
upstream or at the level of Raf.
A candidate for interfering with MAPK signaling upstream
of Raf is the retinoid-inducible gene 1 protein, which was
shown to block MAP kinase pathway downstream events of
all Ras isoforms irrespective of whether Ras was activated by
mutation or growth factors (Tsai et al., 2006). This inhibition
of Ras action has been suggested to be mediated through both
downregulation of Ras expression and through alteration of
Ras subcellular distribution. An alternative mechanism of
MAP kinase silencing in MCC cells might be mediated by the
recently described Prohibitin, which was shown to be
required for Ras-induced activation of the Raf-MEK-ERK
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module (Rajalingam et al., 2005). Moreover, several
phosphorylation as well as dephosphorylation events are in-
volved in Raf activation (Mercer and Pritchard, 2003).
Therefore, several modes of silencing the MAPK pathway
are conceivable.
Upon activation of Raf-ER by OHT in UISO cells, we
observed two major effects, a change in cell morphology and
induction of caspase-dependent apoptosis. A spindle-shaped
morphology associated with the breakdown of actin stress
fibers has been described for Raf transformed NIH3T3
fibroblasts (Kerkhoff and Rapp, 1997). This morphological
transformation is regarded as part of the transformation
process. The loss of adhesion to the tissue culture plate in
vitro has been interpreted as mimicking the loss of anchorage
to the extracellular matrix and thus the ability to migrate out
of the natural tissue in vivo (Kerkhoff et al., 2002). This
interpretation seems unlikely for an already transformed
tumor cell line such as UISO, which has been established
from a highly metastatic MCC, and therefore, we propose that
the morphological changes rather reflect disturbances in
signal transduction pathways regulating cell adhesion and
actin stress fiber formation. Indeed, actin stress fibers are
maintained by the action of the small G-Protein Rho (Hall,
1998). Raf-ER activation may interfere with signaling down-
stream of Rho, as sustained Raf/ERK activation was shown
to downregulate expression of Rho-associated coiled-coil-
containing protein kinase (ROCK) and Rho-kinase, two
Rho effectors required for actin stress fiber formation (Sahai
et al., 2001).
Recently, induction of apoptosis following Raf-ER activa-
tion has also been described for human embryonic kidney
293 cells (Cagnol et al., 2006). Cell death occurred through
activation of caspase-8, but was independent of the death
receptor FAS and the death receptor adaptor Fas-associated
death domain protein. Moreover, the Raf-ER-induced apop-
tosis did not involve the mitochondrial apoptosis pathway.
These and our observations are in contrast to the multiple
examples where Raf signaling actually protects cells against
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Figure 4. The MEK inhibitor U0126 inhibits ERK phosphorylation, morphological alterations, and cell death in OHT-stimulated UISO-Raf-ER cells.
UISO-Raf-ER or UISO-vector control cells were seeded with 0.5105 cells/well in 48-well plates, followed the next day by addition of either OHT to a
final concentration of 200 nM or of the solvent EtOH. U0126 or the solvent DMSO was added at the indicated concentrations simultaneously with OHT or EtOH.
(a) Twenty-four hours after OHT stimulation of UISO-Raf-ER cells in the presence of the indicated concentration of the U0126 total cell lysates were
harvested and subjected to Western blot analysis for phospho-ERK and b-tubulin. (b) Cell death induced by OHT stimulation of UISO-Raf-ER cells is partially
blocked by U0126. The proportion of cells after treatment with OHT or EtOH in the presence or absence of U0126 not excluding trypan blue determined
in a Neubauer chamber was plotted against time. (c) Light microscopy photographs of UISO-Raf-ER cells following a 24-h incubation in the presence of
OHTþDMSO, EtOHþDMSO, and OHTþ30 mM U0126. Bar¼ 100mm.
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Figure 5. Induction of ERK phosphorylation and morphological alterations in
UISO cells by the Raf-activating compound ZM336372. UISO cells were
seeded with 0.5105 cells/well in 48-well plates. After 1 day, ZM336372
was added at the indicated concentrations and ERK phosphorylation was
detected by Western blot analysis 24 hours later.
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programmed cell death, frequently by inhibiting the mito-
chondrial pathway of apoptosis (Wang et al., 1996; Zhong
et al., 2001; Baccarini, 2002; Gotz et al., 2005).
MEK is the best characterized substrate of Raf, but the
existence of additional Raf substrates and alternative Raf
effectors has been demonstrated (O’Neill et al., 2004). By the
use of the MEK inhibitor U0126, we show that the alterations
in cell shape as well as the induction of apoptosis following
activation of Raf-ER in UISO cells are both mediated via
MEK/ERK signaling. Additional lines of evidence that the
morphological changes induced by activated Raf is MAP
kinase signaling-dependent stem from experiments using a
mutant Raf protein with kinase activity but impaired MEK
binding (Pearson et al., 2000). Moreover, consistent with our
observation, it was recently shown that Raf-induced apopto-
sis in human embryonic kidney 293 cells was strictly
dependent on MEK signaling (Cagnol et al., 2006).
Raf and MEK kinase inhibitors are currently tested in
clinical trials for their effectiveness in the treatment of several
cancers, particularly renal cell carcinoma and melanoma
(Thompson and Lyons, 2005). However, the use of com-
pounds with an opposite impact has recently been suggested
to be useful for the treatment of certain neuroendocrine
tumors like medullary thyroid cancer, carcinoid, and
pheochromocytoma (Kunnimalaiyaan and Chen, 2006b).
A study demonstrating that activated Raf-ER inhibits tumor
growth in a xenograft model of human medullary thyroid
cancer indicates that this hypothesis is no more exclusively
based on in vitro data. A possible use of MAP kinase pathway
activating agents for the treatment of MCC is highlighted
by our findings.
MATERIALS AND METHODS
Cell culture
The MCC cell line UISO, which has been established from a primary
MCC of a 46-year-old woman (Ronan et al., 1993), was grown in
Roswell Park Memorial Institute 1640 supplemented with 10% fetal
bovine serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin. To
determine the viability of the cells, detached and adherent cells were
pooled, pelleted, and resuspended in trypan blue solution. Subse-
quently, the percentage of cells excluding trypan blue was
determined using a Neubauer chamber. OHT (Sigma, Tautkirchen,
Germany), U0126 (Calbiochem, Frankfurt, Germany), Z-VAD-FMK
(R&D Systems, Minneapolis, MN), and ZM336372 (Calbiochem)
were added to the culture medium; the stock solutions were 200 mM
in EtOH, 10 mM in DMSO, 10 mM in DMSO, and 10 mM in DMSO,
respectively. The corresponding amount of the appropriate solvent
was added to the culture medium of the control cells. The study
analyzing exclusively established cell lines was conducted accord-
ing to the Declaration of Helsinki Principles.
Retroviral transduction
The bicistronic retroviral vector pEYZ has been published previously
(Kuss et al., 1999). To obtain pEYZ-c-Raf-1-BXB-ERTM, the EcoRI
fragment of BJ4-BxB-ERTM (Kerkhoff and Rapp, 1997) encoding the
c-Raf-1 kinase domain fused to the ligand-binding domain of the
estrogen receptor was cloned into the EcoRI site of pEYZ. Retro-
viruses were raised in human embryonic kidney 293 T cells
transfected with pHIT60 and pVSVg helper constructs in addition
to either pEYZ empty vector or pEYZ-c-Raf-1-BXB-ERTM. Two days
following transfection, virus supernatants were harvested and filtered
through 0.45mm pore size filters. UISO cells were incubated for 3
days in the presence of virus supernatants, and stably transduced
cells were selected in medium containing Zeocin (100 mg/ml). As
controls, the melanoma cell lines Skmel28, Mel2a and FM88 and the
MCC cell lines MCC13 and MCC26 were infected with the same
retroviral vectors and selected as described for UISO cells.
Western blot analysis
For protein analysis, cells cultured under the indicated conditions
were lysed on ice in six-well plates using Laemmli buffer (130 mM
Tris/Cl pH 6.8, 4% SDS, 20% glycerol, 20 mg/ml bromphenol blue,
4% 2-mercaptoethanol). Testing different methods to harvest cells
had revealed that by direct lysis in Laemmli buffer the phospho-ERK
signal was preserved best. Cell lysates were resolved by SDS-PAGE
and transferred to nitrocellulose membranes. Following blocking for
1 hour with phosphate-buffered saline (PBS) containing 0.05%
Tween 20 and 5% powdered skim milk, blots were incubated for
2 hours or over night with primary antibody, washed three times with
PBS supplemented with 0.05 % Tween 20, and then incubated with
the appropriate peroxidase-coupled secondary antibody (DAKO
Cytomation, Germany). Following extensive washing, the bands
were detected using a chemo luminescence detection kit (Roche
Diagnostics, Germany). The primary antibodies used were the
monoclonal antibodies, a-Phospho-p44/42 MAP kinase (Thr202/
Tyr204) (clone E10; Cell Signaling, Beverly, MA) and a-b-tubulin
(Sigma) and the polyclonal antibodies a-RKIP (Upstate, Charlottes-
ville, VA), a-p44/42 MAP kinase, a-Phospho-MEK1/2 (Ser217/221)
(both Cell Signaling, Beverly, MA), and a-pan Raf (30 K; a generous
gift of Ulf R Rapp (Kerkhoff and Rapp, 1997)).
Fluorescence staining
For fluorescence staining, cells were seeded on sterile coverslips.
Following a 48-hour incubation in the presence of OHT or EtOH,
cells were washed three times with ice cold PBS and subsequently
fixed with 4% paraformaldehyde in PBS for 10 min at 371C. After
three washes with PBS at room temperature, cells were permeabi-
lized with 0.2% Triton X-100 in PBS for 3 min at room temperature,
followed again by two washes. Blocking of unspecific binding sites
was carried out with 1% BSA in PBS for 1 h at room temperature.
Then the cells were incubated for 30 min at 371C with 1 U of Alexa
Fluor 488 tagged phalloidin in 60 ml 1% BSA in PBS. Following two
washes, cells were stained with 40,6 diamidino-2-phenylindole
(DAPI) (2 mg/ml) for 15 min at 41C. Cells were washed twice with
PBS and once with distilled water. Cells were covered with Mowiol
(Merck, Frankfurt, Germany) and dried for 2 h at room temperature
and subsequently over night at 41C. Then cells were analyzed using
a confocal fluorescence microscope (True Confocal Scanner Leica
TCS SP II).
Detection of DNA content
Cells in the supernatant as well as cells that still attached to the
culture plate were harvested and resuspended in 0.5 ml. PBS
supplemented with 1% fetal calf serum. Five milliliter of ice-cold
EtOH was added followed by an over night incubation at 41C. The
fixed cells were pelleted and resuspended in 1 ml PBS supplemented
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with 1% fetal calf serum, 0.05 mg/ml propidium iodide, and 0.1 mg/
ml RNase A. Following a 1-hour incubation at 371C, analysis of the
cellular DNA content was performed on a FACSCanto flow
cytometer (Becton & Dickinson, Heidelberg, Germany), and FCS
Express software was used to evaluate data.
Annexin V staining
An Annexin V-Cy5.5 conjugate (BD Biosciences, Heidelberg,
Germany) was used to identify apoptotic cells by flow cytometry
according to the manufacturer’s instructions. Analysis was per-
formed on a FACSCanto using the supplied software (BD
Bioscience).
Our studies were approved by the institutional review board
(Ethik-Kommission der Medizinischen Fakulta¨t der Universita¨t
Wu¨rzburg; sequential study number 135/06).
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